Smoking and Parkinson disease

Objective To investigate whether cigarette smoking interacts with genes involved in individual susceptibility to xenobiotics for the risk of Parkinson disease (PD). Methods Two French population-based case-control studies (513 patients, 1,147 controls) were included as a discovery sample to examine gene-smoking interactions based on 3,179 single nucleotide polymorphisms (SNPs) in 289 genes involved in individual susceptibility to xenobiotics. SNP–by–cigarette smoking interactions were tested in the discovery sample through an empirical Bayes (EB) approach. Nine SNPs were selected for replication in a population-based case-control study from California (410 patients, 845 controls) with standard logistic regression and the EB approach. For SNPs that replicated, we performed pooled analyses including the discovery and replication datasets and computed pooled odds ratios and confidence intervals (CIs) using random-effects meta-analysis. Results Nine SNPs interacted with smoking in the discovery dataset and were selected for replication. Interactions of smoking with rs4240705 in the RXRA gene and rs1900586 in the SLC17A6 gene were replicated. In pooled analyses (logistic regression), the interactions between smoking and rs4240705-G and rs1900586-G were 1.66 (95% CI 1.28–2.14, p = 1.1 × 10−4, p for heterogeneity = 0.366) and 1.61 (95% CI 1.17–2.21, p = 0.003, p for heterogeneity = 0.616), respectively. For both SNPs, while smoking was significantly less frequent in patients than controls in AA homozygotes, this inverse association disappeared in G allele carriers. Conclusions We identified and replicated suggestive gene-by-smoking interactions in PD. The inverse association of smoking with PD was less pronounced in carriers of minor alleles of both RXRA-rs4240705 and SLC17A6-rs1900586. These findings may help identify biological pathways involved in the inverse association between smoking and PD.

[1]  M. Morissette,et al.  Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research , 2017, Neuropharmacology.

[2]  G. Kullak-Ublick,et al.  Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  D. Jennings,et al.  A Phase 1 Clinical Study of the Retinoid X Receptor (RXR) Selective Agonist IRX4204 in Patients with Early Parkinson’s Disease (PD) (P2.342) , 2016 .

[4]  B. Blumberg,et al.  Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease , 2016, Oncotarget.

[5]  Liang Shen,et al.  Associations between Vitamin D Status, Supplementation, Outdoor Work and Risk of Parkinson’s Disease: A Meta-Analysis Assessment , 2015, Nutrients.

[6]  M. Goldberg,et al.  Association of Parkinson’s Disease and Its Subtypes with Agricultural Pesticide Exposures in Men: A Case–Control Study in France , 2015, Environmental health perspectives.

[7]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[8]  K. Mcfarland,et al.  Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. , 2013, ACS chemical neuroscience.

[9]  Y. Nolan,et al.  Parkinson's disease in the nuclear age of neuroinflammation. , 2013, Trends in molecular medicine.

[10]  A. Lees,et al.  Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease , 2012, Annals of neurology.

[11]  O. Dı́az-Ruiz,et al.  Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson’s disease , 2012, BMC Neuroscience.

[12]  Juan Pablo Lewinger,et al.  Invited commentary: GE-Whiz! Ratcheting gene-environment studies up to the whole genome and the whole exposome. , 2012, American journal of epidemiology.

[13]  C. Magnani,et al.  Kin‐cohort analysis of LRRK2‐G2019S penetrance in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[14]  L. Descarries,et al.  Enhanced Sucrose and Cocaine Self-Administration and Cue-Induced Drug Seeking after Loss of VGLUT2 in Midbrain Dopamine Neurons in Mice , 2011, The Journal of Neuroscience.

[15]  J. Houeto,et al.  Impact of recommendations on the initial therapy of Parkinson's disease: a population-based study in France. , 2011, Parkinsonism & related disorders.

[16]  A. Işık,et al.  Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease , 2011, Brain Research Bulletin.

[17]  H. Adami,et al.  Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.

[18]  Eric J Tchetgen Tchetgen,et al.  On the robustness of tests of genetic associations incorporating gene-environment interaction when the environmental exposure is misspecified. , 2011, Epidemiology.

[19]  M. Loriot,et al.  Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. , 2010, Archives of neurology.

[20]  B. Ritz,et al.  After half a century of research on smoking and PD, where do we go now? , 2010, Neurology.

[21]  D. Thomas,et al.  Gene–environment-wide association studies: emerging approaches , 2010, Nature Reviews Genetics.

[22]  Dong Sun Kim,et al.  Epigenetic inactivation of retinoid X receptor genes in non-small cell lung cancer and the relationship with clinicopathologic features. , 2010, Cancer genetics and cytogenetics.

[23]  S. Friling,et al.  Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease , 2009, BMC Neuroscience.

[24]  Jaeil Ahn,et al.  Tests for gene‐environment interaction from case‐control data: a novel study of type I error, power and designs , 2008, Genetic epidemiology.

[25]  Eden R Martin,et al.  A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms , 2008, Genetic epidemiology.

[26]  P. Wilce,et al.  Smoking and alcoholism target genes associated with plasticity and glutamate transmission in the human ventral tegmental area. , 2007, Human molecular genetics.

[27]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[28]  E. Hirsch,et al.  Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease , 2007, Neurobiology of Aging.

[29]  Gunnel Tybring,et al.  Quality and Quantity of Saliva DNA Obtained from the Self-administrated Oragene Method—A Pilot Study on the Cohort of Swedish Men , 2006, Cancer Epidemiology Biomarkers & Prevention.

[30]  C. Tzourio,et al.  Cigarette smoking and Parkinson's disease: A case–control study in a population characterized by a high prevalence of pesticide exposure , 2005, Movement disorders : official journal of the Movement Disorder Society.

[31]  J. Rothstein,et al.  Glutamate transporters: animal models to neurologic disease , 2004, Neurobiology of Disease.

[32]  T. Willson,et al.  Pxr, car and drug metabolism , 2002, Nature Reviews Drug Discovery.

[33]  F. Alla,et al.  Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. , 2000, Cancer research.

[34]  D. Maraganore,et al.  Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990 , 1999, Neurology.

[35]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[36]  P Chambon,et al.  Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. , 1998, Science.

[37]  P. Chambon,et al.  Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W D Flanders,et al.  Sample size requirements in case-only designs to detect gene-environment interaction. , 1997, American journal of epidemiology.

[39]  Richard H. P. Porter,et al.  Glutamate and Parkinson’s disease , 1996, Molecular Neurobiology.

[40]  Xiang‐Dong Wang,et al.  Alcohol and Tobacco Smoke in Retinoid Metabolism and Signaling: Implications for Carcinogenesis , 2006 .